A new oral treatment for ulcerative colitis using synthetic biology.
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
This study is testing a new oral treatment that uses your body's natural gut bacteria to help reduce inflammation and improve symptoms for people with ulcerative colitis, aiming to offer a safer option than some current medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project ID | NIH-11007154 on NIH RePORTER |
What this research studies
This research aims to create a synthetic biology-based oral therapy that utilizes natural microbiome pathways to reduce inflammation in the gut, specifically targeting ulcerative colitis. The approach focuses on harnessing the body's own microbiome to restore the intestinal barrier and regulate immune responses, which are often disrupted in inflammatory bowel disease (IBD). By developing a treatment that is both safe and effective, the researchers hope to provide an alternative to current therapies that may have severe side effects. The project will involve testing this novel therapy in clinical settings to evaluate its efficacy in managing ulcerative colitis symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with ulcerative colitis or other forms of inflammatory bowel disease.
Not a fit: Patients with other gastrointestinal disorders unrelated to inflammatory bowel disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients suffering from ulcerative colitis, potentially improving their quality of life.
How similar studies have performed: While the approach of using synthetic biology in this context is relatively novel, there have been successful applications of microbiome-based therapies in other areas of medicine.
Where this research is happening
Rockville, UNITED STATES
- Rise Therapeutics, LLC — Rockville, United States (Active)
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.